Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome

Background. Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibod...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:medRxiv
المؤلفون الرئيسيون: Borghi, Maria Orietta, Beltagy, Asmaa, Garrafa, Emirena, Curreli, Daniele, Cecchini, Germana, Bodio, Caterina, Grossi, Claudia, Blengino, Simonetta, Tincani, Angela, Franceschini, Franco, Andreoli, Laura, Lazzaroni, Maria Grazia, Piantoni, Silvia, Masneri, Stefania, Crisafulli, Francesca, Brugnoni, Dulio, Muiesan, Maria Lorenza, Salvetti, Massimo, Parati, Gianfranco, Torresani, Erminio, Mahler, Michael, Heilbron, Francesca, Pregnolato, Francesca, Pengo, Martino, Tedesco, Francesco, Pozzi, Nicola, Meroni, Pier Luigi
التنسيق: Artigo
اللغة:Inglês
منشور في: Cold Spring Harbor Laboratory 2020
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310661/
https://ncbi.nlm.nih.gov/pubmed/32588001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.17.20134114
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة